Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.39 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP4B1 | P13584 | 2/20 | 0.38 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.38 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.38 |
| ▸ | CYP2A7 | P20853 | 2/20 | 0.38 |
| ▸ | CYP3A7 | P24462 | 2/20 | 0.38 |
| ▸ | CYP2F1 | P24903 | 2/20 | 0.38 |
| ▸ | CYP2C18 | P33260 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | CYP2J2 | P51589 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15552915 | 0.80 | KIF11 (0.53) | ALDH1A1TAAR1CYP3A4KIF11CA1 | |
| SCHEMBL1465852 | 0.80 | CA1 (0.50) | ALDH1A1TAAR1CYP3A4KIF11CA1 | |
| SCHEMBL2898548 | 0.78 | ALDH1A1 (0.42) | ALDH1A1TAAR1CYP1A1CYP1B1CYP1A2 | |
| SCHEMBL26657676 | 0.75 | CYP1A2 (0.44) | ALDH1A1TAAR1CYP1A1CYP1B1CYP1A2 | |
| SCHEMBL2776692 | 0.75 | ALDH1A1 (0.55) | ALDH1A1CYP1A1CYP1B1CYP1A2CYP2E1 | |
| SCHEMBL2891291 | 0.74 | ALDH1A1 (0.38) | ALDH1A1TAAR1CYP1A1CYP1B1CYP1A2 | |
| Ammonia Solution, Strong SCHEMBL8634007 | 0.73 | ALDH1A1 (0.52) | ALDH1A1CYP1A1CYP1B1CYP1A2CYP2E1 | |
| SCHEMBL2898049 | 0.71 | ALDH1A1 (0.35) | ALDH1A1CYP19A1KDM4EGAA | |
| SCHEMBL8621821 | 0.71 | CYP19A1 (0.47) | ALDH1A1TAAR1CYP1A1CYP1B1CYP1A2 | |
| SCHEMBL28323445 | 0.70 | ALDH1A1 (0.39) | ALDH1A1TAAR1CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311975-A1 | CATIONIC TRANSITION METAL CATALYSTS | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2010-12-09 | — | — | US | claimed |
| EP-2215101-A1 | CATIONIC TRANSITION METAL CATALYSTS | Kanata Chemical Technologies Inc. (CA) | 2010-08-11 | — | — | EP | claimed |
| WO-2009055912-A1 | CATIONIC TRANSITION METAL CATALYSTS | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2009-05-07 | — | — | WO | claimed |
| CN-101730656-B | Method for the production of hydrogen from ammonia borane | 卡娜塔化学技术股份有限公司 | 2017-05-03 | — | — | CN | disclosed |
| US-8518368-B2 | Method for the production of hydrogen from ammonia borane | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2013-08-27 | — | — | US | disclosed |
| US-20110070152-A1 | METHOD FOR THE PRODUCTION OF HYDROGEN FROM AMMONIA BORANE | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2011-03-24 | — | — | US | disclosed |
| US-20100311975-A1 | CATIONIC TRANSITION METAL CATALYSTS | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2010-12-09 | — | — | US | disclosed |
| EP-2215101-A1 | CATIONIC TRANSITION METAL CATALYSTS | Kanata Chemical Technologies Inc. (CA) | 2010-08-11 | — | — | EP | disclosed |
| EP-2158154-A1 | METHOD FOR THE PRODUCTION OF HYDROGEN FROM AMMONIA BORANE | Kanata Chemical Technologies Inc. (CA) | 2010-03-03 | — | — | EP | disclosed |
| WO-2009055912-A1 | CATIONIC TRANSITION METAL CATALYSTS | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2009-05-07 | — | — | WO | disclosed |
| WO-2008141439-A1 | METHOD FOR THE PRODUCTION OF HYDROGEN FROM AMMONIA BORANE | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2008-11-27 | — | — | WO | disclosed |
| US-6878838-B2 | Chiral porous metal phosphonates for heterogeneous asymmetric catalysis | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2005-04-12 | — | — | US | disclosed |
| WO-2004084834-A2 | CHIRAL POROUS METAL PHOSPHONATES FOR HETEROGENEOUS ASYMMETRIC CATALYSIS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2004-10-07 | — | — | WO | disclosed |
| US-20040192543-A1 | Chiral porous metal phosphonates for heterogeneous asymmetric catalysis | NORTH CAROLINA AT CHAPEL HILL, UNIVERSITY OF, THE | 2004-09-30 | — | — | US | disclosed |
| US-20030045727-A1 | Process for preparing optically active secondary alcohols having nitrogenous or oxygenic functional groups | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2003-03-06 | — | — | US | disclosed |
| EP-1254885-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE SECONDARY ALCOHOLS HAVING NITROGENOUS OR OXYGENIC FUNCTIONAL GROUPS | Asahi Kasei Kabushiki Kaisha (JP) | 2002-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045727-A1 | Process for preparing optically active secondary alcohols having nitrogenous or oxygenic functional groups | ADH1A, ADH5, ADH1C | ALDH1A1 85/4885TAAR1 132/4885CYP1A1 223/4885 |
| US-20100311975-A1 | CATIONIC TRANSITION METAL CATALYSTS | AP2M1, OPRM1, CD81 | ALDH1A1 3759/4885TAAR1 634/4885CYP1A1 4357/4885 |
| US-20040192543-A1 | Chiral porous metal phosphonates for heterogeneous asymmetric catalysis | ZKSCAN2, TPRKB, KHK | ALDH1A1 4320/4885TAAR1 3369/4885CYP1A1 3935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.